BriaCell Therapeutics Corp. Revenue and Competitors

Location

#8086

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • BriaCell Therapeutics Corp.'s estimated annual revenue is currently $3.7M per year.(i)
  • BriaCell Therapeutics Corp.'s estimated revenue per employee is $155,000

Employee Data

  • BriaCell Therapeutics Corp. has 24 Employees.(i)
  • BriaCell Therapeutics Corp. grew their employee count by 4% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is BriaCell Therapeutics Corp.?

ABOUT BRIACELL BriaCell (TSXV: BCT) (OTCQB: BCTXF) is a clinical stage immuno-oncology focused biotechnology company developing the first off the shelf personalized immunotherapy for cancer. The company is conducting a Phase IIa clinical trial for its lead product candidate, Bria-IMT™, in advanced breast cancer along with the co-development of BriaDX™, its companion diagnostic. Additionally, there is an FDA approved combination study of Bria-IMT™ with pembrolizumab or ipilimumab for patients with advanced breast cancer previously treated with Bria-IMT™. Moreover, BriaCell is developing Bria-OTS™, the first “off the shelf” personalized treatment for advanced stage Breast Cancer. BriaCell's small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases. For additional information on BriaCell, please visit our website: http://briacell.com/

keywords:N/A

N/A

Total Funding

24

Number of Employees

$3.7M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.7M24-11%N/A
#2
$3.8M244%N/A
#3
$2.4M2420%N/A
#4
$3.7M24N/AN/A
#5
$3.5M249%N/A